AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10613168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsiflexion night splint for 3 months along with oral antiinflammatory medication, Achilles stretching exercises, and shoe recommendations
Number of subjects: 116
Study 10613168 — intervention group
Group type: COMPARATOR
Intervention: Oral antiinflammatory medication, Achilles stretching exercises, and shoe recommendations for 1 month
Number of subjects: 116
Study 10613168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (with and without night splint)
Number of subjects: 116
Study 10613168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 116
Study 10613168 — intervention group
Group type: EXPERIMENTAL
Intervention: Age older than 45 years
Number of subjects: 116
Study 10613168 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Short Form 36 data
Number of subjects: 116
Study 7861873 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in saturated fat and cholesterol
Number of subjects: 1062
Study 7861873 — intervention group
Group type: COMPARATOR
Intervention: Control (unrestricted diet)
Number of subjects: 1062
Study 1773711 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified pork insulin (PPI)
Number of subjects: 9
Study 1773711 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (HI)
Number of subjects: 9
Study 7002185 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g four times daily for 2 days, then 0.5 g four times daily for the next 2 days
Number of subjects: 24
Study 7002185 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 24
Study 7002185 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 24
Study 30171655 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-fampridine
Number of subjects: 55
Study 28692772 — intervention group
Group type: EXPERIMENTAL
Intervention: ReS2 lateral heterojunctions to WS2
Number of subjects: 0
Study 28692772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertically stacked ReS2 on WS2
Number of subjects: 0
Study 28692772 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of anisotropy of ReS2 on WS2
Number of subjects: 0
Study 26555330 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 21
Study 26555330 — intervention group
Group type: COMPARATOR
Intervention: Group intervention
Number of subjects: 21
Study 26555330 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual and Group interventions
Number of subjects: 21
Study 25364070 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive workload (HW) + Sleep Restriction (SR)
Number of subjects: 63
Study 25364070 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate cognitive workload (MW) + Sleep Restriction (SR)
Number of subjects: 63
Study 25364070 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive workload (HW) + No Sleep Restriction (NSR)
Number of subjects: 63
Study 25364070 — intervention group
Group type: COMPARATOR
Intervention: Moderate cognitive workload (MW) + No Sleep Restriction (NSR)
Number of subjects: 63
Study 22139541 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo Capsule
Number of subjects: 239
Study 22139541 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangxin Capsule
Number of subjects: 239
Study 19098197 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D sonography with perflubutane contrast agent
Number of subjects: 84
Study 17684211 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 10 mg tablet twice a day during hospitalization
Number of subjects: 299
Study 17684211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 15051694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemispheric TIA
Number of subjects: 603
Study 15051694 — intervention group
Group type: COMPARATOR
Intervention: Hemispheric stroke
Number of subjects: 603
Study 15051694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemispheric TIA with infarct on brain imaging
Number of subjects: 603
Study 15051694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemispheric TIA with intracranial major-artery disease
Number of subjects: 603
Study 11124350 — intervention group
Group type: COMPARATOR
Intervention: Closed-container condition
Number of subjects: 2
Study 11124350 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside-container condition
Number of subjects: 2
Study 11124350 — intervention group
Group type: COMPARATOR
Intervention: Behind-container condition
Number of subjects: 2
Study 9205830 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan 200 mg orally every 12 h for 4 days
Number of subjects: 12
Study 9205830 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.6 mg orally alone
Number of subjects: 12
Study 8166054 — intervention group
Group type: EXPERIMENTAL
Intervention: Various therapies designed to impact on progression of heart failure
Number of subjects: 0
Study 3308164 — intervention group
Group type: EXPERIMENTAL
Intervention: oral cyclical combination of 2 mg estradiol valerate and cyproterone acetate
Number of subjects: 110
Study 3308164 — intervention group
Group type: COMPARATOR
Intervention: oral placebo
Number of subjects: 110
Study 3308164 — intervention group
Group type: EXPERIMENTAL
Intervention: percutaneous 17 beta‐estradiol, supplemented by 200 mg oral progesterone during the second year
Number of subjects: 110
Study 3308164 — intervention group
Group type: COMPARATOR
Intervention: percutaneous placebo cream
Number of subjects: 110
Study 30124566 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive conditioning task (repeatedly pairing self‐relevant words with an image of a smiling face)
Number of subjects: 28
Study 30124566 — intervention group
Group type: COMPARATOR
Intervention: Neutral conditioning task (repeatedly pairing self‐relevant words with random smiling, angry, or neutral faces)
Number of subjects: 28
Study 27342215 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based care plus community-based rehabilitation
Number of subjects: 182
Study 27342215 — intervention group
Group type: COMPARATOR
Intervention: Facility-based care alone
Number of subjects: 182
Study 23732264 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte A
Number of subjects: 46
Study 23732264 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 46
Study 22789911 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare device kit including monitoring of oxygen saturation, pulse rate, and respiration rate, with medication and purse-lip breathing reminders.
Number of subjects: 40
Study 22789911 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare device kit
Number of subjects: 40
Study 22789911 — intervention group
Group type: COMPARATOR
Intervention: No extra care
Number of subjects: 40
Study 20804255 — intervention group
Group type: EXPERIMENTAL
Intervention: Captain's Log CCRT training (10 sessions)
Number of subjects: 60
Study 20804255 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study 18262446 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 123
Study 18262446 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 123
Study 16160624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg daily)
Number of subjects: 93
Study 16160624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (200 mg daily)
Number of subjects: 93
Study 12749829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazolidinones
Number of subjects: 0
Study 12749829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic peptides
Number of subjects: 0
Study 12749829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopeptide antibiotics
Number of subjects: 0
Study 12749829 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide deformylase inhibitors
Number of subjects: 0
Study 12749829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleuromutilins
Number of subjects: 0
Study 10587868 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-hold contrast-enhanced MR angiography using a multiecho gradient-echo technique
Number of subjects: 16
Study 8726671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative extracorporeal ultrafiltration and postoperative autotransfusion of shed mediastinal blood
Number of subjects: 3
Study 8726671 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion only
Number of subjects: 3
Study 8726671 — intervention group
Group type: COMPARATOR
Intervention: No interventions (control group)
Number of subjects: 3
Study 1928809 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa 250 mg administered orally
Number of subjects: 36
Study 1928809 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study 1928809 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg orally (peripheral DA2 dopamine receptor blocker)
Number of subjects: 36
Study 6137167 — intervention group
Group type: COMPARATOR
Intervention: Lormetazepam
Number of subjects: 0
Study 6137167 — intervention group
Group type: COMPARATOR
Intervention: Lormetazepam (oral and intravenous)
Number of subjects: 0
Study 30700332 — intervention group
Group type: EXPERIMENTAL
Intervention: One-lead handheld ECG recordings twice daily and extra recordings in case of palpitations.
Number of subjects: 1600
Study 30700332 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical practice for AF detection.
Number of subjects: 1600
Study 29668467 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (Group I)
Number of subjects: 60
Study 29668467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound guided rectus sheath block with 40 ml of 0.25% bupivacaine after induction of general anesthesia (Group II)
Number of subjects: 60
Study 26997419 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 24
Study 26997419 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 24
Study 25118980 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB surgery
Number of subjects: 40
Study 25118980 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 40
Study 25118980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 25118980 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative selenium levels
Number of subjects: 40
Study 25118980 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium levels
Number of subjects: 40
Study 22818552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 150
Study 22818552 — intervention group
Group type: COMPARATOR
Intervention: Artesunate plus mefloquine (A+M)
Number of subjects: 150
Study 18801760 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 768
Study 18801760 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab monotherapy
Number of subjects: 768
Study 18801760 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 768
Study 17141580 — intervention group
Group type: EXPERIMENTAL
Intervention: LC‐MS/MS bioanalytical method for clopidogrel
Number of subjects: 0
Study 15105384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic surgery plus intrauterine application of ACP gel (10 ml)
Number of subjects: 132
Study 15105384 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopic surgery alone (control group)
Number of subjects: 132
Study 11437862 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg/day)
Number of subjects: 32
Study 11437862 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (5.0 mg/day)
Number of subjects: 32
Study 9602584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage (group 1)
Number of subjects: 34
Study 8020815 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole once daily
Number of subjects: 104
Study 8020815 — intervention group
Group type: COMPARATOR
Intervention: 2 g sucralfate twice daily
Number of subjects: 104
Study 2920066 — intervention group
Group type: EXPERIMENTAL
Intervention: GE + GU (gemfibrozil + guar gum) 15 g/day
Number of subjects: 29
Study 2920066 — intervention group
Group type: COMPARATOR
Intervention: GE + PL (gemfibrozil + placebo)
Number of subjects: 29
Study 1149485 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 1149485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalorphine
Number of subjects: 0
Study 29206666 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac phonophoresis with combined therapy
Number of subjects: 100
Study 29206666 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac phonophoresis
Number of subjects: 100
Study 29206666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) with coupling gel
Number of subjects: 100
Study 29206666 — intervention group
Group type: COMPARATOR
Intervention: Sham US
Number of subjects: 100
Study 27710914 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate iodine deficiency (ID) group
Number of subjects: 196
Study 23922211 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic mixture (Probinul(®))
Number of subjects: 26
Study 23922211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22741256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dragon-tiger fighting needling method (group A)
Number of subjects: 90
Study 22741256 — intervention group
Group type: COMPARATOR
Intervention: Uniform reinforcing‐reducing method (group B)
Number of subjects: 90
Study 22741256 — intervention group
Group type: COMPARATOR
Intervention: Intermediate frequency physiotherapy (group C)
Number of subjects: 90
Study 20818862 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 512
Study 20818862 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 512
Study 18455403 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 53
Study 18455403 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 53
Study 16481224 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg alone
Number of subjects: 5
Study 16481224 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg with 2‐h spaced calcium carbonate 500 mg thrice daily
Number of subjects: 5
Study 12795568 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family counseling (BFC) plus individual treatment (naltrexone daily in presence of family member)
Number of subjects: 124
Study 12795568 — intervention group
Group type: COMPARATOR
Intervention: Individual-based treatment (IBT; naltrexone with no family involvement)
Number of subjects: 124
Study 11078282 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing low levels of HDL cholesterol
Number of subjects: 0
Study 11078282 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing elevated levels of LDL cholesterol
Number of subjects: 0
Study 9479794 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner medical records
Number of subjects: 150
Study 2066170 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling with a self-help manual and three to eight 15- to 20-min counseling sessions on alternate days while in hospital
Number of subjects: 74
Study 2066170 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no additional counseling)
Number of subjects: 74
Study 6342840 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 3837
Study 6342840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 31662515 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia during breast‐conserving surgery
Number of subjects: 56
Study 31662515 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia during breast‐conserving surgery
Number of subjects: 56
Study 31662515 — intervention group
Group type: COMPARATOR
Intervention: Control group (General anesthesia)
Number of subjects: 56
Study 29895587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 3497
Study 29895587 — intervention group
Group type: COMPARATOR
Intervention: PARADIGM-HF trial participants
Number of subjects: 3497
Study 26856926 — intervention group
Group type: EXPERIMENTAL
Intervention: DP-R202 300 mg once daily
Number of subjects: 151
Study 26856926 — intervention group
Group type: COMPARATOR
Intervention: Anplag Tab 100 mg TID
Number of subjects: 151
Study 25282317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin therapy (rosuvastatin 40 mg or atorvastatin 80 mg)
Number of subjects: 1881
Study 22704854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release morphine (average end titration dose of 78 mg morphine/d)
Number of subjects: 103
Study 22704854 — intervention group
Group type: COMPARATOR
Intervention: Weight-matched placebo capsules
Number of subjects: 103
Study 19449118 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant LHRH agonist plus estramustine phosphate (EMP) for 6 months until completion of the 3D-CRT (EMP group, n = 20)
Number of subjects: 39
Study 19449118 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant LHRH agonist alone (LHRH group, n = 19)
Number of subjects: 39
Study 17035932 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 300 mg
Number of subjects: 16
Study 17035932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15721570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) alone
Number of subjects: 19
Study 15721570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Attachment Based Family Therapy (ABFT)
Number of subjects: 19
Study 12049621 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (50 nmol/min for 60 min)
Number of subjects: 6
Study 12049621 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (300 nmol/min for 5 min followed by saline for 55 min)
Number of subjects: 6
Study 12049621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP; 12 nmol/min for 60 min)
Number of subjects: 6
Study 12049621 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1 (10 pmol/min for 7 min)
Number of subjects: 6
Study 12049621 — intervention group
Group type: EXPERIMENTAL
Intervention: NA (120 pmol/min for 7 min)
Number of subjects: 6
Study 10439495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular prevention programme including opportunistic screening and individually designed follow-up.
Number of subjects: 5622
Study 8607621 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5'-DFUR
Number of subjects: 49
Study 8607621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumor OK-432
Number of subjects: 49
Study 8607621 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5'-DFUR plus intratumor and intracutaneous OK-432
Number of subjects: 49
Study 8607621 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 49
Study 2105625 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rt‐PA)
Number of subjects: 288
Study 108804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate inhalation solution
Number of subjects: 10
Study 108804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate powder
Number of subjects: 10
Study 108804 — intervention group
Group type: COMPARATOR
Intervention: Placebo ampoule
Number of subjects: 10
Study 108804 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 10
Study 29619797 — intervention group
Group type: EXPERIMENTAL
Intervention: H3 (every 3 seconds)
Number of subjects: 9
Study 29619797 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 (every second)
Number of subjects: 9
Study 26744141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated implants in the maxilla
Number of subjects: 48
Study 25797308 — intervention group
Group type: EXPERIMENTAL
Intervention: HHP-processed mango puree (HHP-MP)
Number of subjects: 38
Study 25797308 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed mango puree (unprocessed-MP)
Number of subjects: 38
Study 22897123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based psychotherapy (MBT) for 2 years, twice weekly, combined individual and group therapy
Number of subjects: 85
Study 22897123 — intervention group
Group type: COMPARATOR
Intervention: Supportive group therapy for 2 years, biweekly
Number of subjects: 85
Study 21295639 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with propofol/remifentanil (PCS group)
Number of subjects: 80
Study 21295639 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologist-managed propofol sedation (propofol infusion group)
Number of subjects: 80
Study 19826288 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg group (10 sets of leg extension)
Number of subjects: 24
Study 17269382 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostication system for risk estimation of disability occurrence
Number of subjects: 0
Study 15687772 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed endotracheal suction system (CES)
Number of subjects: 70
Study 15687772 — intervention group
Group type: COMPARATOR
Intervention: Open endotracheal suction system (OES)
Number of subjects: 70
Study 11703246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural patient-controlled analgesia (PCA) using pethidine (bolus 10 mg, lockout interval 10 min, 4-h maximum dose 3 mg.kg(‐1))
Number of subjects: 37
Study 11703246 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) using pethidine (bolus 10 mg, lockout interval 10 min, 4-h maximum dose 3 mg.kg(‐1))
Number of subjects: 37
Study 11703246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural PCA
Number of subjects: 37
Study 11703246 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PCA
Number of subjects: 37
Study 10322828 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhiganle capsule (ZGLC)
Number of subjects: 146
Study 10322828 — intervention group
Group type: COMPARATOR
Intervention: Dongbao Gantai (DBGT) tablets
Number of subjects: 146
Study 8300840 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms orally (up to three doses)
Number of subjects: 60